Yongmei Yin

机构：NewYork–Presbyterian Brooklyn Methodist Hospital, Jiangsu Cancer Hospital, Jiangsu Province Hospital, Jiangsu Provincial Hospital of Traditional Chinese Medicine, Lanzhou University, Nanjing Medical University · ORCID：0000-0003-0225-1471

发表论文 75 篇 · 总被引 1372 次 · h-index 19

代表论文

• Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial (2024 · Journal of Clinical Oncology · 被引 48)
• Intratumoral Collagen Deposition Supports Angiogenesis Suggesting Anti‐angiogenic Therapy in Armored and Cold Tumors (2025 · Advanced Science · 被引 19)
• Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial (2025 · The Lancet Oncology · 被引 8)
• Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after ≥ 2 prior lines of chemotherapy: a phase Ib study (2025 · Nature Communications · 被引 7)
• Evaluation of the safety, pharmacokinetics, and efficacy of JSKN003 in patients with advanced solid tumors: A phase I/II clinical study. (2024 · Journal of Clinical Oncology · 被引 7)
• Precise targeting cytotoxicity of antibody-drug conjugate combined with immunotherapy as first-line regimen for metastatic triple-negative breast cancer in ASCENT-04 (2025 · Translational Breast Cancer Research · 被引 6)